Optimized Anchor-Modified Peptides Targeting Mutated RAS Are Promising Candidates for Immunotherapy

RAS mutations occur in approximately 20% of all cancers and given their clonality, key role as driver mutation, association with poor prognosis and undruggability, they represent attractive targets for immunotherapy. We have identified immunogenic peptides derived from codon 12 mutant RAS (G12A, G12...

Descripción completa

Detalles Bibliográficos
Autores principales: Baleeiro, Renato B., Dunmall, Louisa S. Chard, Liu, Peng, Lu, Shuangshuang, Lone, Yuchun, Lemoine, Nicholas R., Wang, Yaohe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204602/
https://www.ncbi.nlm.nih.gov/pubmed/35720289
http://dx.doi.org/10.3389/fimmu.2022.902709

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9204602/
https://www.ncbi.nlm.nih.gov/pubmed/35720289
http://dx.doi.org/10.3389/fimmu.2022.902709

Ejemplares similares